Cinclus Pharma (Ticker: CINPHA SS) is a clinical-stage pharmaceutical company focused on developing treatments for gastrointestinal diseases. The company is developing linaprazan glurate, a new treatment for erosive gastroesophageal reflux disease (eGERD). Cinclus Pharma will list on June 20, 2024, on Nasdaq Stockholm. Cinclus Pharma is offering approximately 17 million newly issued shares at SEK 42 ($3.89 USD) per share. The total offering is valued at up to SEK 715 million ($66.3 million USD). The offering is managed by Carnegie Investment Bank AB and Bryan Garnier & Co as Joint Global Coordinators and Joint Bookrunners, with ABG Sundal Collier AB as a Joint Bookrunner.